Evidence map›Paper›PMID 38925457›Full record

ArticleThe Journal of molecular diagnostics : JMD2024

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis.

Cristina Iribarren, Kerstin H Levedahl, Ionut Atanasoai, Mattias Mattsson, Martin Höglund, Stina Söderlund, Hans Hägglund, Niclas Eriksson, Marie Carlson, Gunnar P Nilsson

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cristina IribarrenDivision of Immunology and Allergy, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Kerstin H LevedahlDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Ionut AtanasoaiDivision of Immunology and Allergy, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Section of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Mattias MattssonDepartment of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Martin HöglundSection of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Stina SöderlundSection of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Hans HägglundSection of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Niclas ErikssonUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Marie CarlsonGastroenterology Research Group, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Gunnar P NilssonDivision of Immunology and Allergy, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Section of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: gunnar.p.nilsson@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mastocytosis is a heterogeneous disorder characterized by abnormal mast cell accumulation, in which the clinical severity may be explained by distinct molecular mechanisms. This study aimed to explore plasma protein biomarkers associated with systemic mastocytosis subtypes, as well as the cellular origin of the identified proteins. Plasma samples from patients with mastocytosis, including cutaneous mastocytosis (CM), indolent systemic mastocytosis (ISM), and advanced systemic mastocytosis (AdvSM), and a reference group of patients with polycythemia vera, were analyzed by Proximity Extension Assay technology targeting 275 proteins. Furthermore, potential cellular origin was explored using an available single-cell RNA-sequencing data set generated from patients with ISM. The study cohort included 16 patients with CM, 92 patients with systemic mastocytosis (ISM, n = 80; AdvSM, n = 12), and 60 patients with polycythemia vera. A principal component analysis based on 275 plasma proteins revealed one cluster of patients with CM and ISM that was separated from patients with AdvSM. Up to 29 proteins were associated with distinct severe activity in patients with systemic mastocytosis (ISM versus AdvSM), including IL-1 receptor type 1 (IL-1RT1) and tumor necrosis factor ligand superfamily member 13B (TNFSF13B) (q < 0.01). Furthermore, single-cell RNA-sequencing analysis from ISM-derived bone marrow cells revealed that the mRNA for the identified proteins was not exclusive of mast cells. Distinct plasma protein profiles show potential to refine ISM and AdvSM diagnoses, possibly reflecting differences in pathogenic mechanisms and diverse clinical manifestations.

Indexed as

BiomarkersBlood ProteinsMastocytosis, SystemicAdultAgedFemaleHumansMaleMast CellsMiddle AgedProteomicsSingle-Cell AnalysisBiomarkersBlood Proteins

Identifiers

PMID38925457
PMCPMC12178383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.